Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964440 · ClinicalTrials.gov registry record
Redo AF Sub Study (of the Pure EP 2.0 Main Study)
A clinical trial of Atrial Fibrillation Recurrent, sponsored by BioSig Technologies.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT04964440: Completed study of Atrial Fibrillation Recurrent, sponsored by BioSig Technologies.
NCT04964440 is a study of Atrial Fibrillation Recurrent that has completed, run by BioSig Technologies. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04964440, a study of Atrial Fibrillation Recurrent, has completed, sponsored by BioSig Technologies.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a sub study of the Pure EP 2.0 trial. In a redo atrial fibrillation population, this study is designed to collect pulmonary vein signals pre and post ablation therapy, along with other non-pulmonary vein signals of interest during a redo ablation procedure. These signals are later evaluated for clinical relevance and impact on the procedure.
Conditions Studied
Interventions
- DEVICE Pure-EP
Study Locations (1)
Texas
- St. David's Medical Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2022-01-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04964440
The ClinicalTrials.gov registry entry for NCT04964440 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioSig Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation Recurrent appearing as the primary indexed condition, and to 1 intervention - of which Pure-EP is the first listed.
NCT04964440 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04964440 about?
NCT04964440 is a clinical study titled "Redo AF Sub Study (of the Pure EP 2.0 Main Study)". This study is a sub study of the Pure EP 2.0 trial. In a redo atrial fibrillation population, this study is designed to collect pulmonary vein signals pre and post ablation therapy, along with other non-pulmonary vein signals of interest during a redo ablation procedure. These signals are later eval...
What is the current status of trial NCT04964440?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2021-03-03. Estimated completion is 2022-01-29.
What conditions does trial NCT04964440 study?
This clinical trial studies the following conditions: Atrial Fibrillation Recurrent.
What interventions are being tested in trial NCT04964440?
The interventions under investigation include: Pure-EP (DEVICE).
Who is sponsoring clinical trial NCT04964440?
This trial is sponsored by BioSig Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04964440 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.